Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa. It inhibits the binding of TNF alpha (both soluble and membrane-bound). It inhibits its interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. Adalimumab is a biologic drug that blocks the development of inflammation in the gastrointestinaltract.
Ellis CR, Azmat CE. Adalimumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 4, 2020.|https://pubmed.ncbi.nlm.nih.gov/32491812/
Townsend CM, Nguyen TM, Cepek J, et al. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2020;5(5):CD012877. Published 2020 May 16. doi:10.1002/14651858.CD012877.pub2|https://pubmed.ncbi.nlm.nih.gov/32413933/